retatrutide triple agonist weight loss trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide Severe Obesity Trial Shows

Side effects tend to subside as your body adjusts to the medication

Jeffrey Egler, Nooms Chief Medical Officer, puts it, lower dose does not mean lower responsibility. In fact, because microdosing requires slower, more deliberate titration, it often demands more oversight than the standard protocol

This is normal physiology reaching a new equilibrium

So do those who inject into areas with less subcutaneous fat

This article outlines what is currently known about retatrutide's adverse effects, addresses questions around libido and sexual health, and explains when to seek medical advice in the UK context

How common are injection site reactions, and how long do they last